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Abstract
Background: Vitamin D is known to be involved in the immune response to hepatitis C virus infection and 
preliminary data suggests that supplementation may improve response to treatment with interferon and ribavirin. 
Methods: The ViaDUCT study was a pilot, multi-centre, randomised, double-blind, placebo-controlled, parallel 
group clinical trial. Participants with hepatitis C who were planned for treatment were recruited and were 
randomised to 100,000 units oral vitamin D3 supplementation or placebo each month whilst undergoing 
treatment with interferon and ribavirin-based regimens. The primary outcome was sustained virologic 
responseat 12 weeks. Secondary outcomes were to identify the proportion of patients who dropped out and to 
assess for any increase in treatment-related toxicity. Study analyses were performed by modified intention to 
treat of the primary outcome which was compared between the two arms using logistic regression. 
Results: 72 participants were randomised; 35 to vitamin D and 37 to placebo. The mean age of participants 
was 42.5 and 41.7 years respectively. The majority of trial participants were male - 25 (71%) in the vitamin 
D arm and 24 (65%) in the placebo arm. Following treatment, 60 (83%) attended for assessment of sustained 
virologic response at 12 weeks. Sustained virologic response was achieved in 82.9% (95%CI 67.3-91.9%) in the 
vitamin D arm and 73.0% (95%CI 57.0-84.6%) in the placebo arm. The odds of sustained virologic response at 
12 weeks in the intervention arm was not significantly greater than in the placebo arm (adjusted odds ratio 
1.74; 95%CI 0.43-6.97, p= 0.44). Adverse events were in keeping with the expected side effect profile of interferon 
and ribavirin based regimens.
Conclusion: Vitamin D supplementation did not significantly improve sustained virologic response when added 
to interferon and ribavirin-based treatment. The apparent effect size observed would require a largertrial to 
establish any true effect of this adjunctive therapy. 
Trial Registration: ClinicalTrials.gov Identifier: NCT02053519, URL: https://clinicaltrials.gov/ct2/show/
NCT02053519, East of Scotland Research Ethics committee: 13/ES/0116
Keywords: Vitamin D, Interferon, Ribavirin, Hepatitis C virus
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Introduction
Hepatitis C virus (HCV) infection is a major global 
health issue. Recent models estimate a global 
prevalence of 1% indicating that over 70 million 
individuals are currently affected with millions of new 
infections occurring annually[1]. Infection often leads 
to chronic hepatitis and ultimately may proceed to 
cirrhosis, hepatocellular carcinoma and death[2]. 
The therapeutic landscape for HCV has evolved 
dramatically in recent years advancing from interferon 
and ribavirin-based regimens to multiple, novel, 
direct-acting antiviral agents. These novel regimens 
are expensive and access remains problematic for 
many individuals affected by HCV[3]. For example, 
a course of sofosbuvir costs $84,000 in the United 
States[4]. Many low and middle-income countries are, 
therefore, likely to continue to rely upon interferon 
and ribavirin based treatment protocols until generic 
manufacturing is permitted or access deals are agreed 
between governments and manufacturers [3] – a 
process that may take many years. Ways to maximise 
the efficacy of interferon/ribavirin regimes are 
therefore likely to be needed, especially in the short to 
medium term, if lower and middle income countries 
are to mount an affordable response to the public 
health challenge posed by hepatitis C infection.
Vitamin D is a term used to describe several fat-soluble 
compounds which play an important role in calcium 
homeostasis and an increasingly recognised role in 
immune function. Most of the required vitamin D is 
produced by the action of ultraviolet B radiation on 
the skin, with only a small contribution from dietary 
sources. Levels of circulating vitamin D metabolites 
are therefore often low in populations living at high 
latitudes, or in people with little exposure to sunlight 
due to other reasons, e.g. illness or conservative dress 
codes[5]. Associations between low circulating 25-
hydroxyvitamin D (25OHD) levels and a wide range 
of illnesses have been noted, including malignancy, 
respiratory infection, autoimmune and cardio-
metabolic diseases and notably, chronic liver disease 
including chronic HCV infection[6, 7]. 
The interplay between vitamin D and chronic liver 
disease has been further investigated in recent years. 
It has been demonstrated that 25OHD levels are 
lower in those with more severe liver dysfunction[8]. 
Interestingly it has also been shown that vitamin 
D levels rise following successful clearance of HCV 
infection [9]. The T-cell response against the virus may 
also rely upon vitamin D suggesting that deficiency 
may impair the immune response [10, 11]. Given the 
key role of the liver in the 25-hydroxylation of vitamin 
D however, observational studies cannot dissect out 
whether low 25OHD levels are a contributor to, or an 
effect of hepatitis C infection. 
Preliminary clinical data does however suggest 
that vitamin D status is associated with response to 
treatment for HCV. In a small study in Italy Bitetto 
et al found that low 25OHD levels were associated 
with a poorer response to interferon and ribavirin 
and that supplementation increased the likelihood 
of response[12].  Both Abu-Mouch et al and Nimer et 
al performed randomised controlled trials in Israeli 
cohorts to establish if vitamin D supplementation 
affected SVR[13, 14]. 
The Abu-Mouch et al trial randomised 72 individuals 
with HCV genotype 1 to treatment with interferon/
ribavirin with or without vitamin D supplementation. 
They found that vitamin D supplementation 
increased SVR in comparison to the control group, 
86% vs 42% (p<0.001)[14]. In the Nimer et al trial, 
of 50 individuals with genotypes 2 and 3 infections, 
vitamin D supplementation was also associated with 
a significant increase in SVR,95% vs 77% (p<0.001)
[13]. SVR was assessed at 24 weeks in these trials as 
was the then standard of care. 
None of these previous studies were placebo-
controlled and none were performed in northern 
European populations – who are those most likely to 
have low 25OHD levels[5]. We therefore performed a 
randomised, placebo-controlled pilot trial in Scotland, 
UK to more rigorously assess the hypothesis that 
vitamin D supplementation would improve SVR when 
added to an interferon and ribavirin based treatment 
regimen.
Methods
General Study Design and Plan
ViaDUCT was a pilot, multicentre, double blind, 
randomised, placebo controlled, parallel group trial 
to examine the effect of year-long course of monthly 
oral vitamin D3 treatment or placebo, on SVR rates in 
patients with HCV infection treated with interferon 
and ribavirin. As this was a pilot trial an important 
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measure was to determine the number of eligible 
individuals consenting to enter a trial of this design as 
well as the rate of recruitment. The trial was approved 
by East of Scotland Research Ethics committee (13/
ES/0116), and Clinical Trials Authorisation was given 
by the UK Medicines and Healthcare Regulatory 
Authority (EudraCT number 2013-003573-10). 
The trial was registered at www.clinicaltrials.gov, 
registration number NCT02053519
Population
Individuals were recruited from viral hepatitis clinics 
in 5 health boards across the National Health Service 
in Scotland: NHS Tayside, NHS Greater Glasgow and 
Clyde, NHS Grampian, NHS Forth Valley and NHS 
Lothian. Inclusion criteria were: patients with known 
HCV infection confirmed by positive PCR, hepatitis C 
genotype 1 or 3, and planned to commence on standard 
HCV therapy, which at the time of trial recruitment 
was interferon/ribavirin based therapy. 
The exclusion criteria were based upon the usual 
standard-of-care contraindications for treatment with 
interferon and ribavirin. In addition those at risk of, or 
known to have, hypercalcaemia were excluded due to 
the endocrine effects of vitamin D supplementation. 
The exclusion criteria were: hepatitis C genotype 
other than 1 or 3, contraindications to interferon or 
ribavirin therapy, estimated GFR <30ml/min/1.73m2 
(by MDRD4 method) [15] currently decompensated 
liver disease characterised by ascites, encephalopathy 
or variceal bleeding, history of renal calculi, serum 
calcium <2.15 or >2.60 mmol/L, history of sarcoidosis 
or metastatic malignancy, hepatocellular carcinoma, 
taking >400 international units of vitamin D per day, 
HIV positive, pregnancy, breastfeeding, of childbearing 
age and not on reliable contraception, or unable to 
provide written informed consent. 
Participant Recruitment
At the screening visit all participants had their medical 
history taken and gave written informed consent. 
Confirmation of HCV diagnosis by viral load by 
polymerase chain reaction (PCR) and viral genotype 
was taken from the last available values in the medical 
notes.
Standard Treatment
Standard HCV therapy with interferon and ribavirin 
was commenced 1-4 weeks after the first dose of 
vitamin D or placebo. Standard treatment for HCV was 
24 weeks. Genotype 1 patients who did not respond 
to therapy at week 4 or 12 had all anti-viral therapy 
stopped. Other genotype 1 patients who did respond 
but did not become virus negative at 12 weeks of 
therapy were continued on a further 24 week course 
of standard therapy, total duration 48 weeks. Those 
who did not respond and stopped antiviral therapy 
did not continue to receive vitamin D or placebo 
for the planned 12 month course in this trial. Those 
participants who continued on 48 weeks of standard 
therapy received the same 12 months of vitamin D or 
placebo but returned at 3 and 6 months post-end of 
treatment for assessment.
Standard therapy for HCV changed as the trial was 
performed and therefore some patients received 
additional antivirals concomitantly with interferon 
and ribavirin. Genotype 1 patients at the outset of the 
study received interferon/ribavirin but later patients 
could also receive telaprevir, boceprevir, simeprevir or 
sofosbuvir at their prescribing physician’s discretion. 
Similarly, Genotype 3 patients at trial outset received 
interferon/ribavirin but later patients could also 
receive sofosbuvir. 
Trial Treatment, Randomisation and Blinding
After successful confirmation of eligibility including 
safety, participants were randomised by the delegated 
nurse to either vitamin D3 or placebo in a double-
blind fashion via a centrally controlled web-based 
GCP compliant randomisation system, run by Tayside 
Clinical Trials Unit (TCTU) to preserve allocation 
concealment. Randomisation was minimised for age 
(≤ 40, > 40) and genotype (1 or 3). 
Oral vitamin D3 or matching placebo was administered 
once a month. Each dose of vitamin D3 or placebo 
was ingested by the participant in the presence of the 
study nurse. Participants were allowed to continue 
all their usual medication throughout the trial. The 
dose of vitamin D3 used was 100,000 units once a 
month (given as 5mls of Vigantoloil per dose [Merck 
KgAA]). Placebo was 5mls of Mygliol oil per dose; also 
provided by Merck KgAA; Mygliol is a medium-chain 
triglyceride used as the base oil in the manufacture 
of Vigantol. Vitamin D and placebo were identical on 
visual inspection and taste, and were dispensed from 
study bottles with no external indication of whether 
the bottle contained vitamin D or placebo. Participants, 
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research nurses recording outcomes, and healthcare 
teams thus remained blinded to treatment allocation.
Trial Outcomes
The primary outcome of the trial was the absence of 
detectable virus in blood, using PCR to detect HCV 
RNA, at 12 weeks, termed sustained virologic response 
(SVR12). This is a recognised surrogate marker 
for the cure of infection. In this trial any record of a 
negative HCV RNA 12 weeks or more after completion 
of treatment was taken as achievement of SVR12. 
Conversely a positive result was taken as failure of 
SVR12. In the absence of an HCV RNA result, for the 
modified intention to treat analysis, the participant 
was assumed to have failed to achieve an SVR. 
Secondary outcomes were to identify the proportion 
of eligible patients undergoing therapy for HCV 
infection who drop out and to assess the effect of 
supplementation with Vitamin D on adherence to 
standard therapy. The number of individuals recruited 
by each site and the rate of recruitment over the 18 
month study period was also recorded (February 
2014 to August 2015). This data was to establish 
recruitment variability across sites and help to inform 
a calculation regarding the required recruitment 
period for a future large study. A further secondary 
outcome was to assess for any increase in the expected 
toxicity of therapy. 
Sample Size Calculation
We estimated that a definitive trial would require 
313 participants in each arm (assuming alpha=0.05 
and beta=0.80) to have 80% power to show an 
improvement in SVR from 70% in the placebo group 
to 80% in the vitamin D group, at an alpha level of 
0.05. The purpose of this pilot trial was not to detect 
this difference, but to estimate the likely effect size 
and recruitment rates to ensure that a future definitive 
trial was adequately powered.  The sample size was 
therefore set at a maximum of 100 patients (50 
randomised to each arm); this sample size was also 
deemed sufficient to demonstrate the ability of each of 
the study centres to recruit and retain subjects in the 
study, another key point for the pilot to address. This 
would enable the feasibility of a future larger study to 
be fully evaluated. 
Statistical Analysis
Study analyses were performed by modified intention 
to treat (mITT) of the primary outcome SVR at 12 
weeks. The evaluable dataset were those randomised 
and receiving at least one dose of vitamin D3 or 
placebo, with those with missing values for SVR 
assumed to have not achieved SVR. The primary 
outcome (SVR12) was compared between the 
two arms utilising logistic regression stratified by 
centre with a parameter indicating arm of trial. The 
primary analysis was an adjusted analysis, adjusting 
for baseline age, sex, genotype, 25OHD level and 
viral load. Further analyses were performed without 
adjustment for baseline variables, and using a per-
protocol approach (excluding those who did not 
attend for SVR measurement). Subgroup analyses 
were not performed in view of the small numbers 
in the trial; such analyses would carry a high risk of 
spurious positive findings.
A 2-sided p value of <0.05 was taken as significant 
for all analyses. All analyses were conducted using 
SAS v9.3 by trial statisticians blind to treatment 
allocation.
Results
72 participants underwent randomisation and 
received the first dose of study medication. 35 were 
randomised to the vitamin D arm and 37 to the placebo 
arm. Flow through the trial is shown in Figure 1.  14 
of the 35 (40%) in the vitamin D arm had a genotype 
1 infection with the remainder having genotype 3 
infection. 14 of the 37 (38%) in the placebo arm had 
genotype 1 infection with the remaining 23 having 
genotype 3 infection.
All received interferon/ribavirin therapy, however, 
within the vitamin D arm four genotype 3 participants 
also received sofosbuvir. Of genotype 1 participants, 
one received telaprevir and another boceprevir, three 
also received sofosbuvir and a further three received 
simeprevir. Within the placebo arm eight genotype 
3 participants received sofosbuvir and among the 
genotype 1 participants, one received boceprevir 
and six received simeprevir. Of the 72randomised 
participants, 60 (83%) had a blood test performed 
for HCV RNA 12 weeks after end of trial medication to 
allow confirmation of achievement of SVR12. Baseline 
details are given in Table 1.
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Changes in 25 OHD Levels across ViaDuct 
Trial
In the Vitamin D intervention group the mean change 
(averaged across all months) in 25OHD levels was 
+16.7 nmol/L (SD 39.5) compared to the placebo 
group where the mean change (averaged across all 
months) was -7.9 nmol/L (SD 21.8). The between-
group difference was 24.7 nmol/L (95% CI 12.2 to 
37.2; p<0.001 by Student’s t-test)
Primary Outcome
The proportion of positive outcome (SVR at 12 weeks) 
was 82.9% (95% CI 67.3 – 91.9%) in the vitamin D 
group, and 73.0% (95% CI 57.0 – 84.6%) in the placebo 
group. The logistic regression analysis showed no 
significant difference between treatment and placebo 
(adjusted odds ratio = 1.74; 95% CI 0.43-6.97; p= 
0.44). A breakdown of the primary outcome by 
genotype and antiviral therapy is available in 
Table 2. 
The results were consistent between the adjusted and 
unadjusted logistic model (Unadjusted odds ratio = 
1.79; 95%CI 0.57-5.60; p=0.32) which were further 
confirmed by a Chi-Square test on the proportion 
of positive SVR12 per treatments (p=0.31). A per 
protocol analysis was also performed as a sensitivity 
analysis and this also showed no significant difference 
in the SVR12 rate between treatment arms.
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Table 1. Baseline characteristics of study participants
Vitamin D Placebo
N 35 37
Mean age (years) (SD) 42.5 (11.6) 41.7 (8.7)
Male sex  (%) 25 (71%) 24 (65%)
Genotype 1 (%)  14 (40%) 14 (38%)
Genotype 3 (%)  21 (60%) 23 (62%)
Mean 25OHD level (nmol/L) (SD) 59 (24) 51 (21)
Mean HCV RNA level (x106 IU/ml) (SD) 2.5 (5.4) 1.2 (1.4)
25OHD: 25-hydroxyvitamin D. HCV: Hepatitis C virus
Table 2. Primary outcome analyses (SVR12)
Variable Vitamin D Placebo
N=35 N=37
SVR12 (mITT) Positive (%) 6 (17.1) 10 (27.0)Negative (%) 29 (82.9) 27 (73.0)
SVR12*
Per protocol
Positive (%) 1 (3.3) 3 (10.0)
Negative (%) 29 (96.7) 27 (90.0)
Gender Female (%) 10 (28.6) 13 (35.1)Male (%) 25 (71.4) 24 (64.9)
Genotype
1
Total achieving SVR  12   11
Interferon and ribavirin 4  5
Intereferon, ribavirin, telaprevir 1 0
Interferon, ribavirin, boceprevir 1 0
Interferon, ribavirin, sofosbuvir 3 0
Interferon, ribavirin, simeprevir 3 6
Total not achieving SVR) 1 1 
Interferon and ribavirin 1 0
Interferon, ribavirin, boceprevir 0 1
Total genotype 1 for which SVR status unknown 1 2
3
Total achieving SVR 17  16
Interferon and ribavirin 13 8
Interferon, ribavirin, sofosbuvir 4 8
Total not achieving SVR (interferon, ribavirin) 0 2 
Total genotype 3 for which SVR status unknown 4 5
*12 missing SVR12 excluded 
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Secondary Outcomes
The Proportion of Eligible Patients Undergoing 
Therapy for HCV Infection Who Drop Out 
In those patients consented to participate in the trial 
as described in the CONSORT diagram above 100 
consented and only 72 started therapy. The major 
reason for this was not fulfilling entry criteria, the 
second commonest reason was failure to attend further 
appointments. 12 /72 (17%) consented participants 
failed to complete the trial. A breakdown of participant 
recruitment and retention by site is provided in table 3. 
The Addition of Vitamin D Supplementation to Interferon and Ribavirin in the Treatment of Hepatitis C 
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Table 3. Recruitment by site
Health board No. randomised Recruitment per month
Recruitment per 
100,000 population
No. with SVR data 
available (%)
NHS Tayside 15 0.8 3.8 12 (80)
NHS Lothian 7 0.4 0.9 5 (71)
NHS Forth Valley 7 0.4 2.3 7 (100)
NHS Greater Glasgow 
and Clyde 39 2.2 3.0 33 (85)
NHS Grampian 4 0.2 0.8 3 (75)
The Effect of Supplementation with Vitamin 
D3 on Adherence to Standard HCV Therapy
The effect of supplementation with Vitamin D3 on 
adherence to standard HCV therapy was assessed 
using survival analysis and plotted using Kaplan-
Meier plots. The survival analysis of time to drop-off or 
study completion (adherence) indicated no significant 
difference between placebo and drug (hazard ratio = 
1.3; 95%CI 0.8 to 2.1; p=0.33). 
Adverse Events
Adverse events in the trial are listed, broken down by 
intervention, in Table 4 by standard listing of numbers 
of each condition. Most events were non-serious and 
were related to expected side effects from interferon/
ribavirin therapy. There was an excess of respiratory 
infections in the vitamin D arm, this is probably 
spurious and a reflection of small numbers, as other 
vitamin D trials have suggested that vitamin D may be 
protective against respiratory infections[16]. 
Table 4. Adverse events
Category Vitamin D Placebo
Blood and lymphatic system disorders 0 4
Ear and labyrinth disorders 0 1
Gastrointestinal disorders 16 21
Immune system disorders 0 1
Worsening Liver function tests 1 2
Metabolic disorders 2 4
Musculoskeletal disorders 2 4
Nervous system disorders 3 7
Psychiatric disorders 13 18
Urinary tract infection 4 0
Other renal/urological disorders 1 0
Reproductive system/breast disorders 2 1
Respiratory tract infection 11 2
Other Respiratory disorders 9 10
Dermatological disorders 18 17
Vascular disorders 2 1
Other Infections (excl respiratory and urinary infections) 2 6
Other 9 8
TOTAL 95 107
Deaths 0 0
Hospitalisations 1 2
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Discussion
Key Findings
We performed the first randomised, placebo-controlled 
parallel grouptrial to investigate the effects of vitamin 
D supplementation on response to interferon-based 
treatment for HCV. We achieved the aim of performing 
a pilot trial to assess the feasibility of recruitment 
to this trial design and to estimate the effect size of 
vitamin D supplementation to allow planning for a 
larger trial.
We observed no significant difference in SVR between 
the vitamin D and placebo groups which was not 
unexpected given the pilot nature of the trial. A trend 
towards improved SVR in the vitamin D group was 
observed (83% vs 73%, p= 0.44) and the groups were 
otherwise matched suggesting that this effect was 
independent of baseline characteristics.
The effect size had not been rigorously investigated 
prior to this study however our effect size was less 
than that seen in previous Israeli studies, which both 
demonstrated a statistically significant increase in 
SVR with vitamin D supplementation [13, 14]. This 
may be related the more rigorous double-blind trial 
design which we adopted.
Strengths
This trial was conducted in a group of patients known 
to have difficulty accessing healthcare and with a 
known high rate of drop-out from care [17]. It was 
therefore predicted that involving this population 
in a research study would be challenging. Despite 
this our study delivered reasonable recruitment and 
retention in a purely National Health Service (NHS) 
environment. Ultimately the drop-out rate observed 
in the study (16.7% dropout post-randomisation) was 
comparable to standard HCV care drop-out rates and 
reflects the real world nature and applicability of the 
study[18, 19].
Limitations
We aimed to recruit 100 participants to the trial 
and ultimately 72 were enrolled and underwent 
randomisation. A key limitation to recruitment was 
the rapidly evolving therapeutic landscape with 
multiple new interferon-free treatments being 
approved and individual preference for these less 
toxic regimens. Extending the study to enable further 
recruitment was not appropriate given the increased 
efficacy and reduced toxicity of these novel antivirals. 
We initially intended to assess for differences between 
individuals who declined trial involvement and those 
who consented. However, this was confounded by 
the adoption of interferon-free regimens during the 
study period and therefore these data has not been 
presented as they are no longer meaningful.
The use of interferon add-on therapies increased 
as the trial progressed and therefore multiple 
participants in both arms of the study received either 
telaprevir, boceprevir, sofosbuvir or simeprevir. Use of 
these agents complicates interpretation of our results, 
however it would have been unethical to withhold 
these from study participants given the dramatically 
increased SVR associated with these new agents. 
Equally the trend towards vitamin D supplementation 
improving SVR is of greater interest given the higher 
use of novel more effective antivirals in the placebo 
arm of our study.
60 of the 72 (83%) participants ultimately attended 
for post-treatment viral PCR to assess for SVR. It is 
therefore unknown if the treatment was effective in 
the other 12 individuals. It is common in HCV therapy 
for 5-10% of patients to drop out of therapy for patient 
related reasons, for a further 5% to have therapy 
stopped for safety side effects and for a further 5% 
to have therapy stopped due to lack of efficacy. Such 
patients are very difficult to keep in follow up to 
collect SVR data when the patient believes the therapy 
has not worked. Our observed dropout rate (17%) 
is therefore in keeping with real world published 
data[18, 19].
The quality of our data was also affected by a 
population of participants with variable attendance 
rates and chaotic lifestyles. Study visits often did not 
take place when planned and not all study procedures 
could be conducted at times planned in the protocol. 
In addition, all study activities were performed by NHS 
staff and not trained research assistants; an approach 
that reflected the pragmatic nature of the trial design 
and the realities of delivering a clinical service to a 
complex group of patients.
Generalisability
This pilot study was not designed to provide 
generalizable conclusions on the efficacy of the 
addition of vitamin D to interferon and ribavirin-
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based HCV treatment. Our result does not warrant a 
change in clinical practice but helps to inform a future 
larger trial. 
Interpretation
Today the Scottish Medicines Consortium (SMC) 
has approved all-oral pan-genotypic regimens for 
HCV with SVR of over 97%[20] Given this it is not 
surprising that it became increasingly challenging 
to recruit patients to a study and treatment which 
was rapidly becoming obsolete. However, it should 
be noted that the novel direct-acting antivirals are 
extremely expensive and funding will be a challenge in 
even the most highly-funded healthcare systems. The 
largest burden of HCV continues to be felt in lower and 
middle income countries (LMICs) and in these nations 
interferon and ribavirin are likely to be of continued 
importance for some years. An economical means to 
augment response to this regimen may, therefore, still 
provide meaningful benefit to both patients and to 
healthcare systems in LMICs.
Given the widespread adoption of direct-acting 
antivirals it is unlikely that a future large trial of 
vitamin D vs. placebo as an adjunct to interferon/
ribavirin therapy will be conducted in any high-income 
country. In addition, using vitamin D as an adjunct to 
these novel therapies is not required given the near 
100% response rates. However, such a trial could be 
performed in LMICs, could still be informative and 
could lead to a change in practice.
Based upon our data such a trial would require 540 
participants (270 per group) to detect a similar 
difference in effect with 80% power, assuming 
alpha=0.05. A larger number of participants would 
initially be required given the anticipated drop-out 
rates. Our trial enrolled 72 participants for which 
60 (83%) have available SVR data. This 17% drop-
out rate is comparable to that seen in other HCV 
treatment studies. Given this, if SVR data were to be 
obtained for 540 participants an initial enrolment and 
randomisation of 650 individuals would be required. 
It is difficult to draw valid conclusions regarding 
recruitment given the previously discussed difficulties 
which we encountered. In total across the 5 Scottish 
health boards we recruited 4 individuals per month 
during the 18 month trial period. A predicted158 
month (13 year) recruitment period to enrol 632 
participants from a majority of the Scottish population 
in a larger study is unachievable. However if this 
were performed in a lower/middle-income country 
recruitment would be less affected by the widespread 
availability of interferon-free regimens. 
The exact treatment regimen to be utilised in any 
future interferon/ribavirin study involving vitamin 
D vs. placebo is unclear and would be dependent 
upon the availability and cost of add-on direct acting 
antivirals which would boost overall efficacy. 
In addition, recent evidence suggests that the monthly 
vitamin D bolus utilised in our study might be less 
effective than daily or weekly dosing and therefore 
a future trial would likely opt for more frequent 
dosing[16]. 
Conclusion
Our study adds further credence to the hypothesis that 
vitamin D plays a crucial role in modulating the immune 
response to infection and inflammation. Whilst novel 
therapeutics have now replaced interferon/ribavirin 
regimens in high-income nations, interferon/ribavirin 
may continue to be an important therapeutic option in 
LMICs. Current evidence is insufficient to recommend 
adding vitamin D to interferon/ribavirin regimens, 
but our results support the case for larger trials of 
vitamin D supplementation as adjunctive therapy in 
patients with HCV treated with interferon/ribavirin. 
Such trials should be conducted in populations likely 
to be treated in this way – i.e. patients in LMICs.
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